TABLE 2.
Selected sociodemographics, risk, and AT(N) plasma biomarker features by adjudicated cognitive status among American Indian participants of the Strong Heart Study (2017–019).
| Overall | Cognitive intact | MCI | Dementia | IN‐MCI | ||
|---|---|---|---|---|---|---|
| Parameter | N = 397 |
N = 181 45.6% |
N = 140 35.3% |
N = 41 10.3% |
N = 35 8.8% |
p‐Value |
| Age, years | 78.0 (4.7) | 77.4 (4.8) | 78.5 (4.7) | 79.8 (4.9) | 77.2 (3.2) | 0.051 |
| Sex, male; % | 30% | 24% | 33% | 32% | 46% | 0.057 |
| Education, years | 13.0 (2.5) | 13.6 (2.4) | 12.7 (2.4) | 12.0 (2.5) | 12.5 (3.0) | 0.001 |
| APOE ε4 carriers; % | 21% | 18% | 19% | 35% | 31% | 0.040 |
| pTau181 pg/mL | 7.5 (13.5) | 7.6 (17.3) | 6.8 (4.7) | 10.2 (18.4) | 6.6 (4.3) | <0.001 |
| Aβ40 pg/mL | 143.4 (44.6) | 140.1 (43.6) | 143.9 (45.3) | 155.8 (41.7) | 143.7 (49.0) | 0.762 |
| Aβ42 pg/mL | 8.4 (2.8) | 8.2 (2.9) | 8.5 (2.9) | 8.8 (2.3) | 8.3 (2.5) | 0.210 |
| Aβ42/40 ratio | 0.059 (0.014) | 0.059 (0.014) | 0.059 (0.014) | 0.057 (0.009) | 0.060 (0.013) | 0.052 |
| GFAP pg/mL | 174.7 (90.0) | 162.2 (80.9) | 175.9 (88.0) | 216.2 (88.6) | 186.5 (125.3) | 0.005 |
| NfL pg/mL | 40.2 (26.6) | 34.9 (21.3) | 42.4 (28.7) | 53.7 (31.1) | 43.7 (30.9) | <0.001 |
Note: Values provided as mean (SD) unless otherwise indicated. p‐values based on one‐way ANOVA (continuous) or chi2 (dichotomous) tests.
Abbreviations: Aβ, amyloid beta; APOE, apolipoprotein E; GFAP, glial fibrillary protein; IN‐MCI, impaired cognition not MCI; MCI, mild cognitive impairment; NfL, neurofilament light chain; pTau, phosphorylated tau.